Effectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer’s Disease | Zendy

David Wilkinson | Zendy; Rachel Schindler | Zendy; Elias Schwam | Zendy; Gunhild Waldemar | Zendy; Roy Jones | Zendy; Serge Gauthier | Zendy; Oscar L. López | Zendy; Jeffrey L. Cummings | Zendy; Yikang Xu | Zendy; Howard Feldman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer’s Disease

Author(s) -

David Wilkinson,

Rachel Schindler,

Elias Schwam,

Gunhild Waldemar,

Roy Jones,

Serge Gauthier,

Oscar L. López,

Jeffrey L. Cummings,

Yikang Xu,

Howard Feldman

Publication year - 2009

Publication title -

dementia and geriatric cognitive disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.026

H-Index - 110

eISSN - 1421-9824

pISSN - 1420-8008

DOI - 10.1159/000241877

Subject(s) - donepezil , placebo , clinical global impression , medicine , population , odds ratio , alzheimer's disease , clinical trial , cognition , dementia , psychology , disease , psychiatry , pathology , alternative medicine , environmental health

Therapeutic endpoints based on reduced clinical worsening represent clinically relevant and realistic goals for patients suffering from progressive neurodegenerative disorders such as Alzheimer's disease (AD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research